Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sangamo Therapeutics (SGMO) EPS (Weighted Average and Diluted) (2020 - 2025)

Sangamo Therapeutics has reported EPS (Weighted Average and Diluted) over the past 6 years, most recently at -$0.11 for Q4 2025.

  • Quarterly results put EPS (Weighted Average and Diluted) at -$0.11 for Q4 2025, up 8.33% from a year ago — trailing twelve months through Dec 2025 was -$0.44 (up 16.98% YoY), and the annual figure for FY2025 was -$0.44, up 10.2%.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.11 at Sangamo Therapeutics, roughly flat from -$0.11 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for SGMO hit a ceiling of $0.12 in Q1 2023 and a floor of -$0.66 in Q2 2023.
  • Median EPS (Weighted Average and Diluted) over the past 5 years was -$0.28 (2022), compared with a mean of -$0.25.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): crashed 3200.0% in 2021 and later soared 140.0% in 2023.
  • Sangamo Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.25 in 2021, then fell by 28.0% to -$0.32 in 2022, then fell by 6.25% to -$0.34 in 2023, then soared by 64.71% to -$0.12 in 2024, then grew by 8.33% to -$0.11 in 2025.
  • The last three reported values for EPS (Weighted Average and Diluted) were -$0.11 (Q4 2025), -$0.11 (Q3 2025), and -$0.08 (Q2 2025) per Business Quant data.